Product/Composition:- | Liraglutide injection |
---|---|
Strength:- | 6 mg/mL |
Form:- | Pre filled Pen |
Reference Brands:- | Saxenda®(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Saxenda® mimics GLP-1 to enhance satiety, delay gastric emptying, and reduce calorie intake. It promotes weight loss by regulating appetite and metabolism. Clinically proven for chronic weight management, it helps patients achieve significant BMI reduction. Benefits include improved metabolic parameters and potential cardiovascular protection. Administered once daily via subcutaneous injection.
Saxenda® (liraglutide 3 mg), a GLP-1 receptor agonist, is FDA-approved for chronic weight management in adults (BMI ≥30 or ≥27 with comorbidities) and adolescents (12+). The EMA approves it for adults only, with similar BMI criteria. Both regulators mandate a boxed warning for thyroid C-cell tumor risk and contraindicate use in patients with personal/family history of MTC or MEN 2. Discontinue if <5% weight loss occurs after 12 weeks. Storage: Refrigerate (2–8°C); stable at ≤30°C (USA) or ≤25°C (EU) post-opening. Platforms like Pharmatradz.com streamline global B2B access to compliant Saxenda® sourcing and licensing.